Clustering data with hclust algorithm for Effects of the Kinase Inhibitor Sorafenib on Muscle Metabolism In Vivo using Non-targeted Metabolomics Analysis tissue). (Study ST000575)

GC POSITIVE ION MODE (Analysis AN000885)
MetaboliteStructureF1F2
C11 hydrocarbonME1695941.030.97
Tetradecanedioic acidME1696540.981.02
Pyruvic acidME1696470.981.02
GlycineME1696210.981.02
Glycerol 1-phosphateME1696200.981.02
Dehydroalanine (possibly from cysteine)ME1696080.981.02
C23 HydrocarbonME1696030.981.02
3-Phosphoglyceric acidME1695790.981.02
beta-Hydroxybutyric acidME1695900.981.02
C22 hydrocarbonME1696020.991.02
Unknown-possibly propylene glycolME1696580.991.01
TyrosineME1696570.991.01
Tryptamine/NorepinephrineME1696560.991.01
ThreonineME1696550.991.01
Succinic acidME1696520.991.01
SqualeneME1696500.991.01
SiloxanesME1696490.991.01
Prunetin or similar isoflavoneME1696450.991.01
Pentadecanoic acid/HexadecanolME1696410.991.01
Pantothenic acidME1696400.991.01
O-MethylphosphateME1696360.991.01
Oleic acidME1696370.991.01
Myristic acid or PentadecanolME1696350.991.01
Myoinositol-2-phosphateME1696340.991.01
MyoinositolME1696330.991.01
MethionineME1696310.991.01
Linoleic acidME1696280.991.01
Isoleucine/LeucineME1696260.991.01
HomoserineME1696240.991.01
HexitolsME1696230.991.01
Heptadecanoic acid/OctadecanolME1696220.991.01
GlutamineME1696190.991.01
Glutamic acidME1696180.991.01
Glucose and other aldohexosesME1696160.991.01
Glucose-6-phosphate or similarME1696170.991.01
Fructose-6-phosphateME1696140.991.01
Docosahexaenoic acidME1696120.991.01
DisaccharideME1696110.991.01
Dehydroascorbic acid (possibly alpha-ketoglutarate)ME1696090.991.01
Citric acid/isocitric acidME1696060.991.01
CholesterolME1696050.991.01
CampesterolME1696040.991.01
C21 HydrocarbonME1696010.991.01
C17 hydrocarbonME1695990.991.01
C13 hydrocarbonME1695960.991.01
C12 hydrocarbonME1695950.991.01
beta-MonopalmitinME1695910.991.01
Benzoic acidME1695890.991.01
Aspartic acidME1695880.991.01
Arachidonic acid (also Eicosapentaenoic acid)ME1695870.991.01
Arachidic acid/ 1-HeneicosanolME1695860.991.01
alpha-MonostearinME1695840.991.01
AdenineME1695800.991.01
1,5-AnhydroglucitolME1695760.991.01
2-HydroxypyridineME1695780.991.01
ValineME1696601.001.00
UreaME1696591.001.00
Stearic acidME1696511.001.00
SerineME1696481.001.00
Phosphoric acidME1696441.001.00
PhenylalanineME1696431.001.00
PentitolsME1696421.001.00
Palmitic acidME1696381.001.00
Malic acidME1696301.001.00
LysineME1696291.001.00
Lactic acidME1696271.001.00
Fumaric acidME1696151.001.00
Fructose or similar ketohexoseME1696131.001.00
deuterated Myristic Acid (RTL std)ME1696101.001.00
C19 hydrocarbonME1696001.001.00
C15 hydrocarbonME1695981.001.00
C14 HydrocarbonME1695971.001.00
beta-MonostearinME1695921.001.00
alpha-MonopalmitinME1695831.001.00
2-Aminoadipic acidME1695771.001.00
AlanineME1695821.001.00
C10 hydrocarbonME1695931.010.99
CreatinineME1696071.010.99
Palmitoleic acidME1696390.971.03
Adenosine/InosineME1695810.971.03
Aminomalonic acidME1695850.971.03
MSTFA artifactME1696320.961.05
HypotaurineME1696250.951.04
PyrophosphateME1696460.961.04
TaurineME1696530.961.04

Factors:

F1Vehicle (PBS) Control Treatment:30 mg/kg Sorafenib Treatment
F2Vehicle (PBS) Control Treatment:Vehicle (PBS) Control Treatment
Data matrix
  logo